Systemic markers of interferon-γ-mediated immune activation and long-term prognosis in patients with stable coronary artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 698-704

  Pedersen, Eva Ringdal ^a   Midttun, Øivind ^d   Ueland, Per Magne ^a,e   Schartum Hansen, Hall ^a,c   Seifert, Reinhard ^e   Igland, Jannicke ^b   Nordrehaug, Jan Erik ^a,e   Ebbing, Marta ^e   Svingen, Gard ^e   Bleie, Øyvind ^e   Berge, Rolf ^a,c,e   Nygård, Ottar ^a,c,e  

^a Institute of Medicine   (Norway)

^b Institute of Public Health and Primary Health Care   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d BEVITAL AS   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

angina pectoris; epidemiology; immune system; risk factors

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GAMMA INTERFERON; KYUNERNINE; NEOPTERIN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; STABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; KAPLAN-MEIER ESTIMATE; KYNURENINE; MACROPHAGES; MALE; MIDDLE AGED; NEOPTERIN; NORWAY; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 79952194201     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.219329     Document Type: Article

References (36)

1. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-1217. (Pubitemid 35373551)
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
3. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(suppl 6A):9S-16S.
4. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897-1908.
5. McLaren JE, Ramji DP. Interferon γ: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 2009;20:125-135.
6. Fuchs D, Avanzas P, Arroyo-Espliguero R, Jenny M, Consuegra-Sanchez L, Kaski JC. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem. 2009;16:4644-4653.
7. Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem. 2009;55:1135-1146.
8. Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon CP, Braunwald E. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation. 2007;115:3071-3078.
9. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J. 2005;26:457-463. (Pubitemid 40314761)
10. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol. 2004;93:627-629. (Pubitemid 38293075)
11. Schnabel RB, Schulz A, Messow CM, Lubos E, Wild PS, Zeller T, Sinning CR, Rupprecht HJ, Bickel C, Peetz D, Cambien F, Kempf T, Wollert KC, Benjamin EJ, Lackner KJ, Munzel TF, Tiret L, Vasan RS, Blankenberg S. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J. 2010;31:3024-3031.
12. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006; 364:82-90. (Pubitemid 43120630)
13. Wirleitner B, Rudzite V, Neurauter G, Murr C, Kalnins U, Erglis A, Trusinskis K, Fuchs D. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest. 2003;33:550-554. (Pubitemid 36783213)
14. Niinisalo P, Oksala N, Levula M, Pelto-Huikko M, Jarvinen O, Salenius JP, Kytomaki L, Soini JT, Kahonen M, Laaksonen R, Hurme M, Lehtimaki T. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study. Ann Med. 2010;42:55-63.
15. Zhu S, Melcer T, Sun J, Rosbrook B, Pierce JP. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med. 2000;18:305-311. (Pubitemid 30224565)
16. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000; 21:1502-1513.
17. Midttun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009;23:1371-1379.
18. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707-1723.
19. Hastie T, Sleeper L, Tibshirani R. Flexible covariate effects in the proportional hazards model. Breast Cancer Res Treat. 1992;22:241-250.
20. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172; discussion 207-212. (Pubitemid 351193639)
21. R Development Core Team. R: a language and environment for statistical computing. 2008. http://www.R-project.org. Accessed November 1, 2010.
22. Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N, Eber B, Wilders-Truschnig M, Esterbauer H, Klein W. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol. 1997;30:703-707. (Pubitemid 27397650)
23. Sugioka K, Naruko T, Hozumi T, Nakagawa M, Kitabayashi C, Ikura Y, Shirai N, Matsumura Y, Ehara S, Ujino K, Itoh A, Haze K, Becker AE, Yoshiyama M, Ueda M. Elevated levels of neopterin are associated with carotid plaques with complex morphology in patients with stable angina pectoris. Atherosclerosis. 2010;208:524-530.
24. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol. 2000;35:956-962. (Pubitemid 30189928)
25. Niinisalo P, Raitala A, Pertovaara M, Oja SS, Lehtimaki T, Kahonen M, Reunanen A, Jula A, Moilanen L, Kesaniemi YA, Nieminen MS, Hurme M. Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest. 2008;68: 767-770.
26. Pertovaara M, Raitala A, Juonala M, Lehtimaki T, Huhtala H, Oja SS, Jokinen E, Viikari JS, Raitakari OT, Hurme M. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol. 2007; 148:106-111. (Pubitemid 46364993)
27. Ehrt S, Schnappinger D, Bekiranov S, Drenkow J, Shi S, Gingeras TR, Gaasterland T, Schoolnik G, Nathan C. Reprogramming of the macrophage transcriptome in response to interferon- and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J Exp Med. 2001;194:1123-1140.
28. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503. (Pubitemid 24379627)
29. Herpfer I, Greilberger J, Ledinski G, Widner B, Fuchs D, Jurgens G. Neopterin and 7,8-dihydroneopterin interfere with low density lipoprotein oxidation mediated by peroxynitrite and/or copper. Free Radic Res. 2002;36:509-520. (Pubitemid 36285023)
30. Hoffmann G, Rieder J, Smolny M, Seibel M, Wirleitner B, Fuchs D, Schobersberger W. Neopterin-induced expression of intercellular adhesion molecule-1 (ICAM-1) in type II-like alveolar epithelial cells. Clin Exp Immunol. 1999;118:435-440.
31. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003;81:247-265. (Pubitemid 36904332)
32. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V, Celermajer DS, Mellor AL, Keaney JF Jr, Hunt NH, Stocker R. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16:279-285.
33. Adachi T, Naruko T, Itoh A, Komatsu R, Abe Y, Shirai N, Yamashita H, Ehara S, Nakagawa M, Kitabayashi C, Ikura Y, Ohsawa M, Yoshiyama M, Haze K, Ueda M. Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions. Heart. 2007;93:1537-1541. (Pubitemid 350205545)
34. van der Wal AC, Becker AE, Koch KT, Piek JJ, Teeling P, van der Loos CM, David GK. Clinically stable angina pectoris is not necessarily associated with histologically stable atherosclerotic plaques. Heart. 1996;76: 312-316. (Pubitemid 26355979)
35. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150: 341-353. (Pubitemid 29383482)
36. Welsh P, Packard CJ, Sattar N. Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar. Curr Opin Lipidol. 2008;19:563-571.